Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	513.61M
Revenue (ttm)	14.98M
Net Income (ttm)	-119.39M
Shares Out	61.44M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	736,090
Open	8.24
Previous Close	8.31
Day's Range	8.05 - 8.62
52-Week Range	2.91 - 12.40
Beta	1.30
Analysts	Buy
Price Target	14.67 (+75.48%)
Earnings Date	Nov 7, 2024

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1ᵦ/NLRP...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 133
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE
• Website: https://www.monterosatx.com

Analyst Forecast

According to 3 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $14.67, which is an increase of 75.48% from the latest price.

Price Target

$14.67

(75.48% upside)

Analyst Consensus: Buy